Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
SKYE
Stock Latest News
Ratings
Skye Bioscience: Nimacimab’s Emerging Clinical Profile and Undervalued Asymmetric Risk/Reward Support Buy Rating
11d ago
SKYE
Premium
Company Announcements
Skye Bioscience Reports Promising Phase 2a Obesity Data
11d ago
8K
SKYE
Premium
The Fly
Skye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab
11d ago
SKYE
Premium
The Fly
Skye Bioscience presents poster on efficacy of Nimacimab
15d ago
SKYE
Premium
Market News
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/14/26
30d ago
CLB
VTI
Premium
The Fly
Skye Bioscience provides 2026 corporate outlook
1M ago
SKYE
Premium
Class Action
What Investors Can Learn from the Skye Bioscience Securities Fraud Allegations: A Risk Assessment Guide
1M ago
SKYE
Premium
Market News
VTI ETF Daily Update — 1/7/26
1M ago
RPT
VTI
Premium
Ratings
Skye Bioscience: ENHANZE Partnership Unlocks Nimacimab Dosing, De-Risks Phase 2b Path and Supports Buy Rating
1M ago
SKYE
Premium
The Fly
Skye Bioscience, Halozyme enter collaboration, license agreement
1M ago
HALO
SKYE
Premium
The Fly
Halozyme, Skye Bioscience announce global collaboration, license agreement
1M ago
HALO
SKYE
Premium
Company Announcements
Skye Bioscience Collaborates with Halozyme on Nimacimab Delivery
2M ago
8K
SKYE
Premium
Class Action
Skye Bioscience Faces Lawsuit Over Misleading Claims
3M ago
SKYE
Premium
Ratings
Promising Adjunct Potential of Skye Bioscience’s Nimacimab Reinforces Buy Rating
3M ago
SKYE
Premium
Company Announcements
Skye Bioscience Earnings Call: Mixed Signals with Promising Results
3M ago
SKYE
Premium
Company Announcements
Skye Bioscience Reports Promising Q3 2025 Results
3M ago
SKYE
Premium
The Fly
Skye Bioscience reports Q3 EPS (32c), consensus (32c)
3M ago
SKYE
Premium
Pre-Earnings
SKYE Earnings this Week: How Will it Perform?
3M ago
SKYE
Premium
The Fly
Skye Bioscience to present topline data from CBeyond on nimacimab
3M ago
SKYE
Premium
The Fly
Largest borrow rate increases among liquid names
4M ago
SLI
VOR
Premium
Ratings
Buy Rating for Skye Bioscience: Nimacimab’s Potential in Enhancing Obesity Treatment Efficacy
4M ago
SKYE
Premium
Market News
Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
4M ago
MU
VZ
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
